Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue for Immunotherapy-related CRS and ICANS
NCT07169487Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methylene blue in cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence and type of methylene blue-related serious adverse events at Day 35, Impact of Methylene Blue on CAR-T/T Cell Expansion in Peripheral Blood at Day 35 and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
methylene blue
03
Conditions
cytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT07169487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169487.